Skip to main content
. 2021 Jun 18;218(8):e20210151. doi: 10.1084/jem.20210151

Table 1. Genomic MKRN3 aberrations with KRAS mutations in human NSCLCs.

Sample ID Cancer type Stage MKRN3 KRAS
nsclc_mskcc_2018s51 NSCLC NA R102Kfs*28 G13C
LUAD-RT-S01777 Lung adenocarcinoma IIIB P362Hfs*34 G12A
TCGA-62-8398-01 Lung adenocarcinoma IIIA S118L G12D
LUAD-NYU408 Lung adenocarcinoma IB A203G G12V
nsclc_mskcc_2018s26 NSCLC NA Q281K G12C
TCGA-78-7166-01 Lung adenocarcinoma IIB W347C G12C
TCGA-O2-A52Q-01 Lung squamous cell carcinoma III R401W G13C
TCGA-64-5775-01 Lung adenocarcinoma IIIA P411Q Q61L
LUAD-S00488 Lung adenocarcinoma IIIA Hom Del G12C
TCGA-44-8117-01 Lung adenocarcinoma IB Hom Del L19F
TCGA-64-1677-01 Lung adenocarcinoma IIIA Hom Del G12C
TCGA-86-7953-01 Lung adenocarcinoma IA Hom Del G12D
TCGA-95-7039-01 Lung adenocarcinoma IIB Hom Del D33E
TCGA-95-A4VP-01 Lung adenocarcinoma IIIA Hom Del G12V

The co-occurrence of MKRN3 aberrations with KRAS mutations in human lung cancer datasets. Data from lung cancer patients obtained from TCGA lung cancer studies. Sample IDs as well as the precise mutations identified in these patients are indicated. Hom del, homozygous deletion; NA, not available.